Procept Operating Margin from 2010 to 2024
| PRCT Stock | USD 95.59 1.70 1.75% |
Check Procept Biorobotics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Procept Biorobotics' main balance sheet or income statement drivers, such as Net Interest Income of 1.9 M, Interest Income of 5.8 M or Depreciation And Amortization of 3.6 M, as well as many indicators such as Price To Sales Ratio of 13.81, Dividend Yield of 0.0 or PTB Ratio of 7.41. Procept financial statements analysis is a perfect complement when working with Procept Biorobotics Valuation or Volatility modules.
Procept | Operating Margin |
Latest Procept Biorobotics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Procept Biorobotics Corp over the last few years. It is Procept Biorobotics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Procept Biorobotics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.38) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Procept Operating Margin Regression Statistics
| Arithmetic Mean | (5.41) | |
| Coefficient Of Variation | (50.29) | |
| Mean Deviation | 2.31 | |
| Median | (7.06) | |
| Standard Deviation | 2.72 | |
| Sample Variance | 7.39 | |
| Range | 6.2579 | |
| R-Value | 0.80 | |
| Mean Square Error | 2.91 | |
| R-Squared | 0.63 | |
| Significance | 0.0004 | |
| Slope | 0.48 | |
| Total Sum of Squares | 103.46 |
Procept Operating Margin History
About Procept Biorobotics Financial Statements
Procept Biorobotics shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Procept Biorobotics investors may analyze each financial statement separately, they are all interrelated. The changes in Procept Biorobotics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Procept Biorobotics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. Procept Biorobotics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 234 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.